Jerry Griffin, VP of Sales & Marketing at BayMedica, Inc. – a subsidiary of InMed Pharmaceuticals Inc INM – was a guest on Benzinga’s All Access.
InMed is a clinical stage biopharma company that develops drugs based on rare cannabinoids. The company has several drugs in the development pipeline that target ailments as diverse as glaucoma and neurodegenerative diseases.
The company’s subsidiary, Baymedica, produces synthetic cannabinoids for the health and wellness sector.
Watch the full interview here:
Featured photo by Hans Reniers on Unsplash
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.